Who makes Medium Dose-VIS649?

Medium Dose-VIS649 is developed by Visterra, Inc..

What development phase is Medium Dose-VIS649 in?

Medium Dose-VIS649 is in Phase 2.

Last reviewed 2026-04-19 · How we verify

Medium Dose-VIS649

Visterra, Inc. · Phase 2 active Small molecule

At a glance

Generic name	Medium Dose-VIS649
Sponsor	Visterra, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Efficacy Study of VIS649 for IgA Nephropathy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Medium Dose-VIS649 CI brief — competitive landscape report
Medium Dose-VIS649 updates RSS · CI watch RSS
Visterra, Inc. portfolio CI